Drug
Srp 9003
Srp 9003: highest development phase Phase 3, developed by Sarepta Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SRP-9003 NCT06246513 | Phase 3 | Limb-girdle Muscular Dystrophy |
| SRP-9003 NCT03652259 | Phase 1/2 | Limb-Girdle Muscular Dystrophy, Type 2E |
| SRP-9003 NCT05876780 | Phase 1 | Limb Girdle Muscular Dystrophy |
Latest
No recent events.
Follow Srp 9003 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.